NASDAQ:RGEN
Repligen Corporation Stock News
$171.94
+0.91 (+0.532%)
At Close: May 17, 2024
Gamida (GMDA) Up on Omidubicel BLA Rolling Submission Plan
03:39pm, Thursday, 20'th Jan 2022 Zacks Investment Research
The FDA agrees to the initiation of rolling submission of Gamida's (GMDA) BLA for its lead blood cancer candidate, omidubicel. The stock rises more than 22% on in response.
Should Vanguard S&P MidCap 400 Growth ETF (IVOG) Be on Your Investing Radar?
11:20am, Wednesday, 19'th Jan 2022 Zacks Investment Research
Style Box ETF report for IVOG
Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
11:20am, Monday, 17'th Jan 2022 Zacks Investment Research
Smart Beta ETF report for PBE
These Are 5 of the Fastest-Growing Large-Cap Stocks on the Planet
12:20pm, Thursday, 13'th Jan 2022 The Motley Fool
And they're built to remain among the world's fastest-growing companies as well.
Vertex (VRTX) Kaftrio Gets Europe Nod for CF in Children
03:42pm, Wednesday, 12'th Jan 2022 Zacks Investment Research
The European Commission approves Vertex's (VRTX) triple combination therapy, Kaftrio, in combination with Kalydeco for treating cystic fibrosis in children aged between six and 11 years.
Down 16.5% in 4 Weeks, Here's Why Repligen (RGEN) Looks Ripe for a Turnaround
03:00pm, Monday, 10'th Jan 2022 Zacks Investment Research
Repligen (RGEN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising
Down 16.5% in 4 Weeks, Here's Why Repligen (RGEN) Looks Ripe for a Turnaround
11:30am, Monday, 10'th Jan 2022
Repligen (RGEN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising
Repligen Corp. Shares Close the Week 21.9% Lower - Weekly Wrap
07:57am, Monday, 10'th Jan 2022 Kwhen Finance
Repligen Corp. (RGEN) shares closed this week 21.9% lower than it did at the end of last week. The stock is currently down 21.9% year-to-date, down 0.8% over the past 12 months, and up 524.7% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Shares traded as high as $265.78 and as low as $204.10 this week.Shares closed 36.8% below its 52-week high and 27.4% above its 52-week low.Trading volume this week was 13.1% higher than the 10-day average and 57.8% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and beats it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 190.2% The company's stock price performance over the past 12 months lags the peer average by -117.5% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 12.0% higher than the average peer.
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.
The 1-Minute Market Report - January 8, 2022
06:35am, Monday, 10'th Jan 2022 Seeking Alpha
Commodities were the only major index to gain ground last week. Read here for a detailed review...
Here's Why You Should Hold Onto Acadia Healthcare (ACHC) Now
02:58pm, Friday, 31'st Dec 2021 Zacks Investment Research
Acadia Healthcare (ACHC) is poised for growth due to higher revenues driven by solid demand for behavioral health services, multiple JVs with established healthcare systems and debt repayment efforts.
J&J (JNJ) Seeks FDA Approval for Myeloma Drug Teclistamab
11:33pm, Thursday, 30'th Dec 2021 Zacks Investment Research
J&J (JNJ) submits a Biologics License Application, seeking approval for its bispecific antibody candidate teclistamab as a treatment option for the heavily pretreated multiple myeloma patients.
Repligen Corporation to Present at 40th Annual J.P. Morgan Healthcare Conference
12:30pm, Thursday, 30'th Dec 2021 GlobeNewswire Inc.
WALTHAM, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present vir
Repligen Corporation to Present at 40th Annual J.P. Morgan Healthcare Conference
07:30am, Thursday, 30'th Dec 2021
WALTHAM, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtu
Is Invesco S&P MidCap 400 Pure Growth ETF (RFG) a Strong ETF Right Now?
06:48pm, Wednesday, 29'th Dec 2021 Zacks Investment Research
Smart Beta ETF report for RFG
Pluristem (PSTI) Misses Study Goal to Treat COVID-Related ARDS
05:04pm, Tuesday, 28'th Dec 2021 Zacks Investment Research
Pluristem's (PSTI) phase II studies evaluating PLX-PAD cells for treating acute respiratory distress syndrome associated with COVID-19 fail to achieve the primary endpoint.